Echinocandin

Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan in the fungal cell wall via noncompetitive inhibition of the enzyme 1,3-β glucan synthase.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 4 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan in the fungal cell wall via noncompetitive inhibition of the enzyme 1,3-β glucan synthase. The class has been dubbed the "penicillin of antifungals," along with the related papulacandins, as their mechanism of action resembles that of penicillin in bacteria. β-glucans are carbohydrate polymers that are cross-linked with other fungal cell wall components, the fungal equivalent to bacterial peptidoglycan.

Caspofungin, micafungin, and anidulafungin are semisynthetic echinocandin derivatives with limited clinical use due to their solubility, antifungal spectrum, and pharmacokinetic properties.

]] Echinocandins are a class of antifungal drugs that inhibit the synthesis of β-glucan in the fungal cell wall via noncompetitive inhibition of the enzyme 1,3-β glucan synthase. The class has been dubbed the "penicillin of antifungals," along with the related papulacandins, as their mechanism of action resembles that of penicillin in bacteria. β-glucans are carbohydrate polymers that are cross-linked with other fungal cell wall components, the fungal equivalent to bacterial peptidoglycan.

Caspofungin, micafungin, and anidulafungin are semisynthetic echinocandin derivatives with limited clinical use due to their solubility, antifungal spectrum, and pharmacokinetic properties.

Side effects

All three agents are well-tolerated, with the most common adverse effects being fever, rash, nausea, and phlebitis at the infusion site. They can also cause a histamine-like reaction (flushing) when infused too rapidly. Toxicity is uncommon. Its use has been associated with elevated aminotransferases and alkaline phosphatase levels.

Interference

Caspofungin has some interference with ciclosporin metabolism, and micafungin has some interference with sirolimus (rapamycin), but anidulafungin needs no dose adjustments when given with ciclosporin, tacrolimus, or voriconazole.

Advantages

Advantages of echinocandins: Broad range (especially against all Candida), thus can be given empirically in febrile neutropenia and stem cell transplant Can be used in case of azole-resistant Candida or use as a second-line agent for refractory aspergillosis Long half-life (polyphasic elimination: alpha phase 1–2 hours + beta phase 9–11 hours + gamma phase 40–50 hours) Low toxicity: only histamine release (3%), fever (2.9%), nausea and vomiting (2.9%), and phlebitis at the injection site (2.9%), very rarely allergy and anaphylaxis Not an inhibitor, inducer, or substrate of the cytochrome P450 system, or P-glycoprotein, thus minimal drug interactions Lack of interference from kidney failure and hemodialysis No dose adjustment is necessary based on age, gender, race Better (or no less effective) than amphotericin B and fluconazole against yeast (mainly Candida, NOT yeast form of dimorphic) infections

Disadvantages

Disadvantages of echinocandins: Cryptococcus, Trichosporon, and zygomycetes are often resistant to echinocandins and they show weak activity against yeast forms of Histoplasma, Blastomyces, and Coccidioides. Embryotoxic in animal studies (category C) thus should be avoided if possible in pregnancy Some need adjustment of dosing for patients with liver disease. Poor ocular penetration in fungal endophthalmitis

Examples

List of echinocandins: Pneumocandins (cyclic hexapeptides linked to a long-chain fatty acid) Echinocandin B not clinically used, risk of hemolysis Cilofungin withdrawn from trials due to solvent toxicity Caspofungin (trade name Cancidas, by Merck) Micafungin (FK463) (trade name Mycamine, by Astellas Pharma.) Anidulafungin (VER-002, V-echinocandin, LY303366) (trade name Eraxis, by Pfizer) Rezafungin formerly CD101 IV, Rezafungin is considered to be safest echinocandins which also acts longest (weekly single dose).

It is developed by Cidara Therapeutics. The STRIVE Trial (phase 2) showed weekly treatment with Rezafungin was safe and efficacious in the treatment of candidemia and/or invasive candidiasis.

See also

Papulacandin B

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330815490 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.